Medical Oncology, Radboudumc, Nijmegen, Netherlands.
Medical Imaging, Radboudumc, Nijmegen, Netherlands.
Front Immunol. 2023 Jun 2;14:1199282. doi: 10.3389/fimmu.2023.1199282. eCollection 2023.
Treatment with immune checkpoint inhibitors (ICI) can induce durable responses in cancer patients, but it is commonly associated with serious immune-related side effects. Both effects are suggested to be mediated by CD8+ T-cell infiltration. Whole body CD8+ T-cell distribution can be visualized by PET imaging of a 89Zr-labeled anti-humanCD8a minibody, currently investigated in a phase 2b trial.
An adult patient diagnosed with metastatic melanoma developed ICI-related hypophysitis after two courses of combined immunotherapy (ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) at 3 weeks interval). On a [Zr]Zr-crefmirlimab berdoxam PET/CT scan, made 8 days before clinical symptoms occurred, increased CD8+ T-cell infiltration in the pituitary gland was detected. Simultaneously, tracer uptake in a cerebral metastasis was increased, indicating ICI-induced tumor infiltration by CD8+ T-cells.
The observations in this case report underscore the role of CD8+ T-cell in non-tumor tissues in ICI-related toxicity. In addition, it illustrates a potential role for molecular imaging by PET/CT for investigation and monitoring of ICI-induced effects.
免疫检查点抑制剂(ICI)的治疗可以在癌症患者中诱导持久的反应,但它通常与严重的免疫相关的副作用相关。这两种作用都被认为是由 CD8+T 细胞浸润介导的。全身 CD8+T 细胞的分布可以通过 PET 成像对 89Zr 标记的抗人 CD8a 单抗进行可视化,目前正在进行 2b 期试验。
一名被诊断患有转移性黑色素瘤的成年患者在接受两周期联合免疫治疗(ipilimumab(3mg/kg)和 nivolumab(1mg/kg),每 3 周一次)后发生 ICI 相关垂体炎。在出现临床症状前 8 天进行的[Zr]Zr-crefmirlimab berdoxam PET/CT 扫描中,检测到垂体中 CD8+T 细胞浸润增加。同时,脑转移瘤的示踪剂摄取增加,表明 CD8+T 细胞诱导的肿瘤浸润。
本病例报告中的观察结果强调了 CD8+T 细胞在 ICI 相关毒性中非肿瘤组织中的作用。此外,它说明了 PET/CT 分子成像在研究和监测 ICI 诱导作用方面的潜在作用。